ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 656

Gene Expression Variation and The Role Of Interferon In Patients With Morphea From The Morphea In Adults and Children Cohort

Daniel Grabell1, Andrew Kim2, Virginia Pascual3, Shervin Assassi4 and Heidi Jacobe1, 1Dermatology, UT Southwestern Medical Center at Dallas, Dallas, TX, 2Lenox Hill Hospital, New York, NY, 3Baylor University, Dallas, TX, 4Rheumatology, University of Texas Health Science Center at Houston, Houston, TX

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Interferons and morphea

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Localized scleroderma (morphea) is characterized by inflammation and sclerosis of the dermis and underlying tissue and may be associated with significant morbidity. Overproduction of type I and III collagen by fibroblasts is thought to be a factor in the pathogenesis of morphea but, little is known about the mechanism by which these fibroblasts are activated.  Endothelial cell injury, immunologic and inflammatory activation, and dysregulation of collagen production have all been proposed.  The purpose of this study is to describe the transcriptosome of lesional morphea skin relative to non-lesional controls.   

Methods: Skin samples from adult patients in the Morphea in Adults and Children Cohort (MAC) with active, untreated lesions were collected from the inflammatory border, sclerotic center, and site matched non-lesional skin.  Gene expression analysis of the three tissue types was conducted using Illumina Human HT4 arrays. The gene expression profile of each tissue type was then compared to that of corresponding normal tissue in a self-controlled fashion.  We considered differentially expressed genes (DEGs) with a cut-off of fold change >2.0 and a p<0.05.  The data was evaluated without correction and with the Benjamini–Hochberg procedure.  Ingenuity Pathway Analysis (IPA) was utilized to identify canonical pathways among differentially expressed genes.  The DEGs were compared to known type I interferon genes as collected by Monash University’s Interferome database. 

Results: Principal components analysis demonstrated a clear difference between gene expression patterns of the inflammatory border and sclerotic center when compared to normal skin and each other.  The total number of DEGs when comparing the inflammatory border (IB) and the sclerotic center (SC) grouped together compared to unaffected skin (UA) was 724.    The number of genes shared between Morphea skin and UA skin was 397.  The number of genes unique to the IB compared with the UA was 647 and to the sclerotic center were 562.  Comparison with the Interferome database showed that 35 IB genes and 23 SC genes overlapped with the interferon pathway.  Specifically we saw that CXCL10, a major component of the interferon pathway, showed a14.3 fold change when compared to normal skin.  Through IPA analysis we showed that the top five pathways include iCOS-iCOSL Signaling in T Helper Cells, CD28 Signaling in T Helper Cells, CTLA4 Signaling in Cytotoxic T Lymphocytes, OX-40 Signaling Pathway, and Dendritic Cell Maturation. 

Conclusion: These results demonstrate that gene expression differs between matched pairs of lesional morphea skin and non-lesional skin from the same patient.  Interestingly the inflammatory border and sclerotic center showed different levels of gene expression with greater activation of CXCL10 in the IB versus the SC, implicating different molecular mechanisms at play in the initiation of lesions. Our results support the theory that therapeutics targeting the CXCL10 pathway may lead to future treatments for Morphea.


Disclosure:

D. Grabell,
None;

A. Kim,
None;

V. Pascual,
None;

S. Assassi,
None;

H. Jacobe,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-variation-and-the-role-of-interferon-in-patients-with-morphea-from-the-morphea-in-adults-and-children-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology